

Subject: RFI Inhalation testing - OncoTheis

Date: Thursday, July 17, 2014 11:32:14 PM Eastern Daylight Time

From: Samuel Constant

To: NIEHS NICEATM

CC: Christophe Mas

Dear Sir or Madam,

In response to your information request on technologies used for inhalation testing, it is my great pleasure to send you some information on OncoTheis. We developed a novel *in vitro* human lung cancer model (OncoCilAir) for the evaluation of **chemotherapies** (including efficacy and local toxicity testing) and **carcinogenic risks**.

You will find attached a description sheet as well supporting information containing representative data.

We stay at your disposal for any question you may have.

With kind regards,

Samuel

--

Samuel CONSTANT, Ph.D., CEO

OncoTheis Sàrl

14, Chemin des Aulx - CH-1228 Plan les Ouates - Geneva - Switzerland

Tel: +41 (0) 22 794 65 16 - Mob: +33 (0) 62 675 85 26 - Fax: +41 (0) 22 794 65 17

www.oncotheis.com

Confidentiality Warning: The information in this email and in any attachment may contain information which is legally privileged. It is intended only for the attention and use of the named recipient. If you are not the intended recipient, you are not authorized to retain, disclose, copy or distribute the message and/or any of its attachments. If you received this email in error, please notify me and delete this message. Thank-you.

Supporting information provided to NICEATM available on request